Logo image of XXII

22ND CENTURY GROUP INC (XXII) Stock Fundamental Analysis

USA - NASDAQ:XXII - US90137F5098 - Common Stock

1.76 USD
+0.02 (+1.15%)
Last: 9/18/2025, 4:11:03 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XXII. XXII was compared to 8 industry peers in the Tobacco industry. While XXII seems to be doing ok healthwise, there are quite some concerns on its profitability. XXII has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XXII has reported negative net income.
In the past year XXII has reported a negative cash flow from operations.
XXII had negative earnings in each of the past 5 years.
In the past 5 years XXII always reported negative operating cash flow.
XXII Yearly Net Income VS EBIT VS OCF VS FCFXXII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

XXII has a Return On Assets of -99.71%. This is amonst the worse of the industry: XXII underperforms 87.50% of its industry peers.
The Return On Equity of XXII (-396.39%) is worse than 62.50% of its industry peers.
Industry RankSector Rank
ROA -99.71%
ROE -396.39%
ROIC N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXII Yearly ROA, ROE, ROICXXII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XXII so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXII Yearly Profit, Operating, Gross MarginsXXII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

XXII does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XXII has been increased compared to 1 year ago.
The number of shares outstanding for XXII has been increased compared to 5 years ago.
Compared to 1 year ago, XXII has an improved debt to assets ratio.
XXII Yearly Shares OutstandingXXII Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
XXII Yearly Total Debt VS Total AssetsXXII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -26.10, we must say that XXII is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -26.10, XXII is doing worse than 62.50% of the companies in the same industry.
There is no outstanding debt for XXII. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.1
ROIC/WACCN/A
WACC7.4%
XXII Yearly LT Debt VS Equity VS FCFXXII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 0.77 indicates that XXII may have some problems paying its short term obligations.
XXII has a worse Current ratio (0.77) than 75.00% of its industry peers.
A Quick Ratio of 0.61 indicates that XXII may have some problems paying its short term obligations.
The Quick ratio of XXII (0.61) is worse than 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.61
XXII Yearly Current Assets VS Current LiabilitesXXII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 98.90% over the past year.
XXII shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -32.51%.
The Revenue has been decreasing by -1.15% on average over the past years.
EPS 1Y (TTM)98.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3680.56%
Revenue 1Y (TTM)-32.51%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-48.64%

3.2 Future

XXII is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.81% yearly.
XXII is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.98% yearly.
EPS Next Y5.25%
EPS Next 2Y41.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-43.66%
Revenue Next 2Y12.98%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XXII Yearly Revenue VS EstimatesXXII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
XXII Yearly EPS VS EstimatesXXII Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 0 -100K -200K -300K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

XXII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
XXII is valuated cheaply with a Price/Forward Earnings ratio of 7.84.
Compared to the rest of the industry, the Price/Forward Earnings ratio of XXII indicates a rather cheap valuation: XXII is cheaper than 100.00% of the companies listed in the same industry.
XXII is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.70, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 7.84
XXII Price Earnings VS Forward Price EarningsXXII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XXII Per share dataXXII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K -2K

4.3 Compensation for Growth

XXII's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as XXII's earnings are expected to grow with 41.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.81%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

XXII does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

22ND CENTURY GROUP INC

NASDAQ:XXII (9/18/2025, 4:11:03 PM)

1.76

+0.02 (+1.15%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners2.2%
Inst Owner Change-86.88%
Ins Owners14.6%
Ins Owner Change0%
Market Cap6.65M
Analysts82.86
Price Target5.1 (189.77%)
Short Float %2.82%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-148.29%
Min EPS beat(2)-181.72%
Max EPS beat(2)-114.86%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-26.42%
Max Revenue beat(2)24.24%
Revenue beat(4)1
Avg Revenue beat(4)-22.45%
Min Revenue beat(4)-55.74%
Max Revenue beat(4)24.24%
Revenue beat(8)1
Avg Revenue beat(8)-24.92%
Revenue beat(12)2
Avg Revenue beat(12)-26.25%
Revenue beat(16)3
Avg Revenue beat(16)-19.83%
PT rev (1m)-92.09%
PT rev (3m)-58.33%
EPS NQ rev (1m)75.59%
EPS NQ rev (3m)-78.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-777.21%
Revenue NQ rev (1m)-49.28%
Revenue NQ rev (3m)-49.28%
Revenue NY rev (1m)-35.44%
Revenue NY rev (3m)-35.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.84
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2190.45
EYN/A
EPS(NY)0.22
Fwd EY12.75%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-3.66
OCFYN/A
SpS5.29
BVpS1.49
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.71%
ROE -396.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.83%
Cap/Sales 0.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.61
Altman-Z -26.1
F-Score4
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)104.4%
Cap/Depr(5y)87.56%
Cap/Sales(3y)9.68%
Cap/Sales(5y)6.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3680.56%
EPS Next Y5.25%
EPS Next 2Y41.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.51%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-48.64%
Revenue Next Year-43.66%
Revenue Next 2Y12.98%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.74%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.04%
OCF growth 3YN/A
OCF growth 5YN/A